Edwards Lifesciences Corporation (EW) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Edwards Lifesciences Corporation (EW) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (78% profit margin, 13% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
How EW Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $6.07B | 78% | 20.8% | $1.07B | $1.33B | 12.5% |
| FY 2024 | $5.44B | 79.5% | 25.3% | $4.17B | $289.9M | 14.4% |
| FY 2023 | $5.01B | 44% | 26.1% | $1.40B | $670.4M | 5.7% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring EW)
- ✓Live walkthrough of EW's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
EW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EW today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EW. Explore sector supply chains on /butterfly.
EW Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Edwards Lifesciences Corporation (EW)?
In FY 2025 (10-K), EW converted $6.1B of revenue into a 78% gross margin, 20.8% operating margin, and $1.3B in free cash flow (22% FCF margin).